Multi-Cancer Early Detection Breath Test
Breast, Lung, Colorectal, Prostate Cancer Screening
Clinical ValidationActive
Key Facts
Indication
Breast, Lung, Colorectal, Prostate Cancer Screening
Phase
Clinical Validation
Status
Active
Company
About SpotitEarly
SpotitEarly is pioneering a multi-cancer early detection (MCED) platform using breath analysis. Its technology combines biological sensors (reportedly leveraging canine olfaction) with a proprietary AI platform named LUCID to analyze VOC signatures associated with cancer. Founded in 2019, the company is in the clinical validation stage, having completed the 'Rainbow Study' and planning further trials, with the goal of commercializing a subscription-based, direct-to-consumer diagnostic service. Its value proposition centers on high reported accuracy (94% sensitivity/specificity for early-stage cancer), ease of use, and scalability.
View full company profile